Skip to main content
ELDN logo

ELDN · Eledon Pharmaceuticals, Inc. · Metrics

Track ELDN — free
$2.62 +0.00 (+0.00%) At close · Nov 3 Q1 2023 earnings call transcript
Market Cap
$212.90M
Shares
81.26M
Volume · Nov 3 403.17K Avg daily vol (3M) 913.96K

ELDN metrics

58 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.62
Market cap
$212.90M

Price action

20 metrics
Price change (1W)
+18.6%
Price change (30D)
+4.8%
Price change (3M)
-23.6%
Price change (6M)
-30.7%
Price change (YTD)
+73.5%
Price change (1Y)
-39.4%
Trailing year
Price change (5Y)
-48.3%
52-week high
$4.36
52-week low
$1.39
Change from 52-week high
-39.9%
Change from 52-week low
+88.5%
Annualized volatility
84.6%
Annualized volatility (3M)
62.7%
Beta
1.9
RSI (14D)
52.7
Price vs SMA 50
-1.8%
Price vs SMA 200
-15.7%
Avg volume (3M)
932,387
Relative volume
0.7
Average dollar volume
$2.72M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
81.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
6.4
reciprocal yield 15.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-46.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-22

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$56.22M
Net income (TTM)
−$98.56M
Trailing 12 months
Diluted EPS (TTM)
$-0.91
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.07

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+47.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-298.6%
Return on assets
-78.2%
Debt / equity
0.0
Current ratio
7.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$88.76M
Latest balance sheet
Cash & equivalents
$6.80M
Total assets
$126.09M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$73.86M
Capital expenditures (TTM)
—
R&D (TTM)
$67.89M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
161
13F filer change QoQ
+38
Institutional ownership
58.8%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
20.9%
Private-fund adviser ownership
19.6%
Active holders' share change QoQ
-0.1%
Holder tenure
10.1
Price vs estimated holder cost
+14.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.5%

Short interest

3 metrics
Short interest
9.7%
Latest settlement · 10.3 days to cover
Days to cover
10.3d
Short-squeeze score
73 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1404281 CUSIP 28617K101 13F (30d) 45 filings 44 filers Visit website Investor relations